• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝切除术后1年内伴或不伴2型糖尿病的BCLC B - C期肝细胞癌患者血糖变异性的外科护理视角分析:一项2016年至2020年的回顾性队列研究

A surgical nursing perspective analysis of glucose variability in BCLC stage B-C hepatocellular carcinoma patients with and without T2D within 1 year of hepatectomy: a retrospective cohort study from 2016 to 2020.

作者信息

Wang Li-Ping, Zhu Jia-Sha, Zhan Feng-Di, Fang Tian, Zhao Li

机构信息

Department of Breast Surgery/Plastic Surgery, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

J Gastrointest Oncol. 2023 Apr 29;14(2):943-951. doi: 10.21037/jgo-23-163.

DOI:10.21037/jgo-23-163
PMID:37201059
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10186515/
Abstract

BACKGROUND

Previous research has reported that variability in glucose levels is associated with a variety of patient characteristics in colon cancer. However, relevant research is still lacking in relation to hepatocellular carcinoma (HCC).

METHODS

A total of 95 HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B-C who underwent liver resection at the Eastern Hepatobiliary Surgery Hospital and Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine were included in this study. The patients were divided into 2 groups with type 2 diabetes (T2D) and without T2D. The primary outcome variable was blood glucose variability at 1 month and within 1 year of HCC surgery.

RESULTS

In this study, the age of patients with T2D was greater than that of patients without T2D (mean age: 70.3±8.45 60.4±11.27 years, P=0.031). Compared to the patients without T2D, those with T2D had higher blood glucose measurements within 1 month (33 7) and 1 year (46.5 22.5, P<0.001) of surgery. The T2D patients and non-T2D patients did not differ in terms of chemotherapy medication or other characteristics. Among the 95 patients with BCLC stage B-C HCC, those with T2D had higher variability in glucose levels (P<0.001) than those without T2D within 1 month of surgery [standard deviation (SD) =46.43 mg/dL, coefficient of variation (CV) =23.5% SD =21.56 mg/dL, CV =13.21%], and within 1 year of surgery (SD =42.49 mg/dL, CV =26.14% SD =20.45 mg/dL, CV =17.36%). A correlation was found between a lower body mass index and higher variability in glucose levels within 1 month of surgery among patients with T2D [SD (r=-0.431, P<0.05) and CV (r=-0.464, P<0.01)]. A higher preoperative blood glucose level in T2D patients was correlated with a higher blood glucose variability within 1 year of surgery (r=0.435, P<0.01). Variability in glucose levels was weakly correlated with the demographic and clinical characteristics of patients who do not have T2D.

CONCLUSIONS

HCC patients with T2D in BCLC stage B-C showed greater variability in glucose levels within 1 month and 1 year of surgery. Preoperative hyperglycemia, insulin use, and a lower cumulative dose of steroids were clinical features correlated with a higher variability in glucose levels in T2D patients.

摘要

背景

先前的研究报道,血糖水平的变异性与结肠癌患者的多种特征相关。然而,关于肝细胞癌(HCC)的相关研究仍然缺乏。

方法

本研究纳入了95例在东方肝胆外科医院和上海交通大学医学院附属新华医院接受肝切除术的巴塞罗那临床肝癌(BCLC)B - C期HCC患者。将患者分为有2型糖尿病(T2D)和无T2D两组。主要结局变量为HCC手术后1个月及1年内的血糖变异性。

结果

在本研究中,T2D患者的年龄大于无T2D的患者(平均年龄:70.3±8.45岁对60.4±11.27岁,P = 0.031)。与无T2D的患者相比,T2D患者在手术后1个月(33±7)和1年(46.5±22.5,P < 0.001)的血糖测量值更高。T2D患者和非T2D患者在化疗药物或其他特征方面没有差异。在95例BCLC B - C期HCC患者中,T2D患者在手术后1个月内的血糖水平变异性高于无T2D的患者(P < 0.001)[标准差(SD)= 46.43mg/dL,变异系数(CV)= 23.5%对SD = 21.56mg/dL,CV = 13.21%],在手术后1年内也是如此(SD = 42.49mg/dL,CV = 26.14%对SD = 20.45mg/dL,CV = 17.36%)。在T2D患者中,发现较低的体重指数与手术后1个月内较高的血糖水平变异性之间存在相关性[SD(r = -0.431,P < 0.05)和CV(r = -0.464,P < 0.01)]。T2D患者术前较高的血糖水平与手术后1年内较高的血糖变异性相关(r = 0.435,P < 0.01)。血糖水平变异性与无T2D患者的人口统计学和临床特征弱相关。

结论

BCLC B - C期合并T2D的HCC患者在手术后1个月和1年内血糖水平变异性更大。术前高血糖、胰岛素使用和较低的类固醇累积剂量是与T2D患者较高血糖水平变异性相关的临床特征。

相似文献

1
A surgical nursing perspective analysis of glucose variability in BCLC stage B-C hepatocellular carcinoma patients with and without T2D within 1 year of hepatectomy: a retrospective cohort study from 2016 to 2020.肝切除术后1年内伴或不伴2型糖尿病的BCLC B - C期肝细胞癌患者血糖变异性的外科护理视角分析:一项2016年至2020年的回顾性队列研究
J Gastrointest Oncol. 2023 Apr 29;14(2):943-951. doi: 10.21037/jgo-23-163.
2
Glycemic Variability Within 1 Year Following Surgery for Stage II-III Colon Cancer.术后 2-3 期结肠癌患者 1 年内血糖变异性。
Biol Res Nurs. 2022 Jan;24(1):64-74. doi: 10.1177/10998004211035184. Epub 2021 Oct 5.
3
Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases.BCLC-B 期肝细胞癌肝切除术的手术和肿瘤学结果:474 例连续病例的回顾性多中心分析。
Updates Surg. 2019 Jun;71(2):285-293. doi: 10.1007/s13304-019-00649-w. Epub 2019 Apr 2.
4
Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia.巴塞罗那临床肝癌指南推荐范围内和范围外的肝细胞癌肝切除术:来自东亚一家大容量肝脏外科中心的结果。
J Surg Oncol. 2020 Dec;122(8):1587-1594. doi: 10.1002/jso.26183. Epub 2020 Aug 19.
5
Evaluation of the up-to-7 criterion for determining the treatment of hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage B: a single-center retrospective cohort study.巴塞罗那临床肝癌分期B期肝细胞癌治疗判定的7项标准评估:一项单中心回顾性队列研究
J Gastrointest Oncol. 2023 Apr 29;14(2):768-779. doi: 10.21037/jgo-23-69. Epub 2023 Apr 11.
6
Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification.巴塞罗那临床肝癌(BCLC)分期 0、A 和 B 期肝细胞癌切除后的预后:对当前 BCLC 分类的综合评估。
Ann Surg Oncol. 2019 Oct;26(11):3693-3700. doi: 10.1245/s10434-019-07580-9. Epub 2019 Jul 2.
7
Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence.巴塞罗那临床肝癌中晚期肝细胞癌手术切除结果的系统评价:证据的批判性评估
World J Hepatol. 2018 Jun 27;10(6):433-447. doi: 10.4254/wjh.v10.i6.433.
8
Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients.肝切除术为选定的中期(BCLC-B)肝细胞癌患者带来生存获益。
Cancer Res Treat. 2019 Jan;51(1):65-72. doi: 10.4143/crt.2018.038. Epub 2018 Feb 26.
9
Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects.连续血糖监测测定的血糖变异性绝对和相对指标相关的临床因素:480例受试者的分析
Diabetes Res Clin Pract. 2014 May;104(2):266-72. doi: 10.1016/j.diabres.2014.02.003. Epub 2014 Feb 22.
10
Enteral Nutrition Preparations for Blood Glucose Variability and Prognosis for Severe Acute Pancreatitis With Stress Hyperglycemia.肠内营养制剂对伴有应激性高血糖的重症急性胰腺炎患者血糖变异性及预后的影响
Altern Ther Health Med. 2023 Jan;29(1):163-169.

本文引用的文献

1
Glycemic Variability in Patients With Stage II-III Colon Cancer Treated With Surgery and Adjuvant Chemotherapy.接受手术和辅助化疗的 II-III 期结肠癌患者的血糖变异性。
Oncol Nurs Forum. 2022 Oct 20;49(6):571-584. doi: 10.1188/22.ONF.571-584.
2
Glycaemic variability and risk of adverse cardiovascular events in acute coronary syndrome.血糖变异性与急性冠状动脉综合征不良心血管事件风险。
Diab Vasc Dis Res. 2022 Nov-Dec;19(6):14791641221137736. doi: 10.1177/14791641221137736.
3
Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1.长链非编码 RNA Linc01612 通过调控 miR-494/ATF3/p53 轴并促进 YBX1 的泛素化来抑制肝癌进展。
Int J Biol Sci. 2022 Apr 11;18(7):2932-2948. doi: 10.7150/ijbs.69514. eCollection 2022.
4
New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.肝细胞癌中检查点抑制剂免疫治疗及其联合治疗的新见解:从机制到临床试验。
Int J Biol Sci. 2022 Mar 28;18(7):2775-2794. doi: 10.7150/ijbs.70691. eCollection 2022.
5
Cancer and its predictors in Chinese adults with newly diagnosed diabetes and impaired glucose tolerance (IGT): a 30-year follow-up of the Da Qing IGT and Diabetes Study.中国新诊断糖尿病和糖耐量受损(IGT)成人中的癌症及其预测因素:大庆 IGT 和糖尿病研究的 30 年随访。
Br J Cancer. 2022 Jul;127(1):102-108. doi: 10.1038/s41416-022-01758-x. Epub 2022 Mar 7.
6
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
7
Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.综合机器学习和生物信息学分析构建了一种新型的干细胞相关分类器,用于预测肝细胞癌患者的预后和免疫治疗反应。
Int J Biol Sci. 2022 Jan 1;18(1):360-373. doi: 10.7150/ijbs.66913. eCollection 2022.
8
Identification and Validation of a Prognostic Model Based on Three MVI-Related Genes in Hepatocellular Carcinoma.基于三个与 MVI 相关基因的肝细胞癌预后模型的鉴定和验证。
Int J Biol Sci. 2022 Jan 1;18(1):261-275. doi: 10.7150/ijbs.66536. eCollection 2022.
9
Diabetes mellitus and postoperative blood glucose value help predict posthepatectomy liver failure in patients with hepatocellular carcinoma.糖尿病和术后血糖值有助于预测肝细胞癌患者肝切除术后肝衰竭。
J Gastrointest Oncol. 2021 Oct;12(5):2377-2387. doi: 10.21037/jgo-21-491.
10
Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients.二甲双胍对糖尿病患者初始肝切除术后肝细胞癌复发的影响。
PLoS One. 2021 Mar 4;16(3):e0247231. doi: 10.1371/journal.pone.0247231. eCollection 2021.